Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Six questions about HIV/AIDS that deserve more attention

As HIV investigators work to control and eradicate the virus worldwide, certain myths or misconceptions about the disease have been embraced, whereas other concepts with merit have been left relatively unexplored, argues American HIV/AIDS researcher Jay Levy, M.D., in a Trends in Molecular Medicine commentary. He calls on fellow researchers to continue questioning and not to lose sight of alternative strategies that could ultimately lead to a sustainable, long-term solution to HIV infection.

Published
15 April 2015
From
Eurekalert Inf Dis
Mechanism of action of ABIVAX’s First-in-class anti-HIV drug published today in peer-reviewed journal Retrovirology

ABX464 blocks viral replication by preventing the export of viral RNA from the nucleus to the cytoplasm in infected cells. This transport is normally mediated by a viral protein called Rev, and the activity of Rev is efficiently inhibited by ABX464. Never targeted before, Rev has been postulated of potential interest for HIV treatment for some time, but ABX464 is the first molecule under development aimed at inhibiting it.

Published
14 April 2015
From
ABIVAX press release
Editing HIV out of our genome with CRISPR

In an attempt to render latent HIV completely harmless, UMass Medical School researchers are using CRISPR/Cas9, a powerful gene editing tool, to develop a novel technology that can potentially cut the DNA of the latent virus out of an infected cell.

Published
13 April 2015
From
University of Massacusetts Medical Schoool press release
Broadly Neutralizing Antibody Suppresses HIV in Clinical Trial

There is now intense interest in learning whether the blossoming array of broadly neutralizing antibodies (bNAbs) can be put to therapeutic and preventive use. A paper published yesterday in Nature describes encouraging results from a phase I trial involving the bNAb 3BNC117. Reflecting the level of interest in the topic, the paper has attracted extensive press coverage.

Published
10 April 2015
From
TAG
In first human study, new antibody therapy shows promise in suppressing HIV infection

The new study, conducted in Michel Nussenzweig’s Laboratory of Molecular Immunology, finds that administration of a potent antibody, called 3BNC117, can catch HIV off guard and reduce viral loads.

Published
09 April 2015
From
Rockefeller University press release
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment

Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) for the treatment of HIV-1 infection in adults and pediatric patients age 12 years and older, in combination with other HIV antiretroviral agents.

Published
08 April 2015
From
Gilead press release
New lead against HIV could finally hobble the virus’s edge

Scientists at Emory University, in partnership with the pharmaceutical company Bristol-Myers Squibb, have found compounds that block the human CCR5 and CXCR4 co-receptors for HIV and also HIV reverse transcriptase, an enzyme that’s key to the virus’s ability to copy itself.

Published
24 March 2015
From
American Chemical Society
HIV treatment: New inexpensive agents can block virus ability to replicate and develop resistance

New and affordable drugs that check the HIV virus from developing resistance are in progress, according to scientists who will present their findings at the 249th National Meeting & Exposition of the American Chemical Society (ACS) in Denver.

Published
20 March 2015
From
International Business Times
Cabotegravir and rilpivirine effective for HIV maintenance therapy at 96 weeks

An combination of two once-daily oral antiretrovirals – the next-generation integrase inhibitor cabotegravir (GSK1265744) and the approved NNRTI rilpivirine (Edurant, also in Eviplera or Complera) – was as effective

Published
19 March 2015
By
Liz Highleyman
Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia

Sangamo's purportedly ground-breaking results in HIV with SB-728 do not stand up under close examination. SB-728 has not shown any indication that it can provide a "functional cure" for HIV, does not compare well to today's standard of care, and cannot find a partner. Sangamo refuses to conduct studies that rigorously assess whether their drugs work. This includes the inclusion of a control arm so assiduously avoided by Sangamo's management.

Published
10 March 2015
From
Seeking Alpha
← First12345...82Next →

Filter by country